These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28991472)

  • 1. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
    Riggs JR; Nagy M; Elsner J; Erdman P; Cashion D; Robinson D; Harris R; Huang D; Tehrani L; Deyanat-Yazdi G; Narla RK; Peng X; Tran T; Barnes L; Miller T; Katz J; Tang Y; Chen M; Moghaddam MF; Bahmanyar S; Pagarigan B; Delker S; LeBrun L; Chamberlain PP; Calabrese A; Canan SS; Leftheris K; Zhu D; Boylan JF
    J Med Chem; 2017 Nov; 60(21):8989-9002. PubMed ID: 28991472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
    Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
    Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
    Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
    Riggs JR; Elsner J; Cashion D; Robinson D; Tehrani L; Nagy M; Fultz KE; Krishna Narla R; Peng X; Tran T; Kulkarni A; Bahmanyar S; Condroski K; Pagarigan B; Fenalti G; LeBrun L; Leftheris K; Zhu D; Boylan JF
    J Med Chem; 2019 May; 62(9):4401-4410. PubMed ID: 30998356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
    Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
    Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.
    Huang CC; Hsu CM; Chao MW; Hsu KC; Lin TE; Yen SC; Tu HJ; Pan SL
    Protein Sci; 2024 Jun; 33(6):e5004. PubMed ID: 38723164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.
    Elsner J; Cashion D; Robinson D; Bahmanyar S; Tehrani L; Fultz KE; Narla RK; Peng X; Tran T; Apuy J; LeBrun L; Leftheris K; Boylan JF; Zhu D; Riggs JR
    J Med Chem; 2021 Sep; 64(17):12670-12679. PubMed ID: 34459599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray Crystal Structure-Guided Design and Optimization of 7
    Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I
    J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy‑stress‑mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple‑negative breast cancer.
    Lim JS; Kim E; Song JS; Ahn S
    Oncol Rep; 2024 Aug; 52(2):. PubMed ID: 38904203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
    Anderhub SJ; Mak GW; Gurden MD; Faisal A; Drosopoulos K; Walsh K; Woodward HL; Innocenti P; Westwood IM; Naud S; Hayes A; Theofani E; Filosto S; Saville H; Burke R; van Montfort RLM; Raynaud FI; Blagg J; Hoelder S; Eccles SA; Linardopoulos S
    Mol Cancer Ther; 2019 Oct; 18(10):1696-1707. PubMed ID: 31575759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
    Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
    PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
    Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
    Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
    Singh U; Chashoo G; Khan SU; Mahajan P; Nargotra A; Mahajan G; Singh A; Sharma A; Mintoo MJ; Guru SK; Aruri H; Thatikonda T; Sahu P; Chibber P; Kumar V; Mir SA; Bharate SS; Madishetti S; Nandi U; Singh G; Mondhe DM; Bhushan S; Malik F; Mignani S; Vishwakarma RA; Singh PP
    J Med Chem; 2017 Dec; 60(23):9470-9489. PubMed ID: 29144137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
    Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
    J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
    Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Ha GH; Kim DY; Breuer EK; Kim CK
    Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.